Sarepta capitalizes on hot streak with $125M financing

A school of thought in biotech calls for raising money, and as much as you can, when the time is right or whenever it's available (depending on circumstances). Sarepta Therapeutics ($SRPT) has seen demand for its stock spike since the company revealed impressive long-term data two months ago from a mid-stage study of its therapy eteplirsen in patients with Duchenne muscular dystrophy. With the stock sizzling since then, Sarepta has gone out and raised an impressive $125 million. Now the company has restocked its coffers as it seeks meetings with U.S. regulators about getting an early nod for the drug for the rare muscle-wasting disease. Hear what CEO Chris Garabedian had to say about the rationale for the deal to The Street. Interview

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.